Tang Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$11.6M |
| 2 |
SPHS
Sophiris Bio, Inc.
SPHS
|
+$2.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$10.5M |
| 2 |
MannKind Corp
MNKD
|
+$7.71M |
| 3 |
ASRT
Assertio
ASRT
|
+$6.85M |
| 4 |
NAVB
Navidea Biopharmaceuticals Inc.
NAVB
|
+$2.32M |
| 5 |
Rockwell Medical
RMTI
|
+$1.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 73.01% |
| 2 | Healthcare | 26.99% |
| 3 | Industrials | 0% |
Similar funds
Tang Capital Management's Q3 2013 Portfolio in Review
As of Q3 2013, Tang Capital Management held 21 positions worth $202M, down 20% from $254M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Tang Capital Management withdrew a net $164M in Q3 2013, closing 4 positions and reducing 1 holding. Its most notable exit was Nektar Therapeutics, an estimated $10.5M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 73% of assets, down from 77% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Tang Capital Management opened a new position in Mirati Therapeutics, Inc. Common Stock worth $17.9M.
- Tang Capital Management's largest Q3 2013 buy was Mirati Therapeutics, Inc. Common Stock: 1,181,400 shares worth $17.9M.
- Tang Capital Management's biggest Q3 2013 reduction was Assertio, cutting an estimated $6.85M.
- Tang Capital Management fully exited Nektar Therapeutics in Q3 2013, selling an estimated $10.5M.
- Tang Capital Management's ten largest holdings make up 91% of its $202M portfolio in Q3 2013.
- Tang Capital Management opened 2 new positions and closed 4 in Q3 2013.
- Tang Capital Management's portfolio value fell 20% quarter-over-quarter to $202M.
Based on Tang Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.